Federated Hermes
LOGC

Federated Hermes’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Federated Hermes’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-526
Closed -$1K – 2340
2022
Q1 		$1K Buy
+526
New +$577 ﹤0.01% 2157

Other funds holding LOGC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Federated Hermes's LOGC Position: Q2 2022 in Review

Federated Hermes sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q2 2022, closing a stake of 526 shares — an estimated $1K sold.

Federated Hermes first reported a position in LOGC in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 47 funds tracked by Wall St. Rank hold LOGC as of Q2 2022.

  • Federated Hermes reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Federated Hermes sold 526 LogicBio Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $1K.
  • Federated Hermes first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Federated Hermes's LogicBio Therapeutics, Inc. Common Stock position peaked at $1K in Q1 2022.
  • 47 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Federated Hermes's 13F filing for Q2 2022, filed 15 Aug 2022.